11 | 18 | 2021

ANGIODYNAMICS

Canaccord Genuity MedTech & Diagnostics Forum 2021

Jim Clemmer, President & CEO Stephen Trowbridge, EVP & CFO



Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "piojects," "believes," "seeks," "estimates," optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, general market conditions, market acceptance, foreign neulth of AngioDynamics to effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign nurrecy exchange rate fluctuations, the effects or portion from group purchasing organizations and competition, the ability of An

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has included adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results.

MED TECH Invest for Growth

Thrombus Management

AngioVac Uni-Fuset

Peripheral Atherectomy



Irreversible Electroporation



angiodynamics



MED DEVICE Maintain Positioning

Vascular Access Catheters and Accessories


Diagnostic Catheters, Guidewires and Kits


Endovenous Laser Treatment

Microwave & Radiofrequency Tumor Ablation

Lung Biopsy Safety


Radiation Treatment Stabilization Balloons





The planned portfolio additions and new indications are not guarantees of future performance and are subject to risks and uncertainties including FDA clearance. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations.

VTE Represents 390k Cases Annually



The AngioVac Difference


The AngioVac System allows for the **continuous aspiration** of embolic material such as fresh, soft thrombi or vegetation from the venous system

Utilizing a self-expanding, nitinol reinforced funnel tip

Simultaneously reinfusing the patient's own filtered blood to limit procedural blood loss







Individual experience may not be indicative of all procedure results.

THE NEXT GENERATION OF ANGIOVAC

Physician requests for use in DVT drive new product development



THE NEXT PORTFOLIO INNOVATION

A purpose-built, innovative product leveraging the strengths of the AngioVac cannula technology with *off-circuit* manual aspiration control

Powerful

Proven funnel tip design allows efficient aspiration and compression of large clot burden


Controlled


Designed to allow the end-user command and control of the mechanical aspiration

Versatile

Broadens Thrombus Management portfolio and is designed to provide an intuitive, first-line treatment option without the need for lytics and advanced procedural support








available for sale in any country.

9



FI8⁸⁵

PE

(Av

33FR

85°

18FR

Cannula

22FR

Sheath

FY24

O4*

F1310

~16FR

10°

~13FR

Cannula

~16FR


Sheath

FY23

O4*

THROMBUS MANAGEMENT

Planned Portfolio Additions & U.S.Addressable Markets Expansion





The planned portfolio additions are not guarantees of future performance and are subject to risks and uncertainties, including clearance by the FDA. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations.

Purpose Built, Comprehensive, Thrombus Portfolio



Continuous Aspiration with Simultaneous Reinfusion F22²⁰ F22¹⁸⁰ F18⁸⁵ I8⁸⁵ PE F13¹⁰

ALPHAVAC

 Multi-purpose Mechanical/Manual Aspiration

 F2220
 F22180
 F1885
 1885 PE
 F1310

Uni-Fuse⁺ Catheter Directed Thrombolysis with PE Indication

11



US Addressable Markets & Competitive Landscape




Over 8 Million² Americans Suffer from PAD

Over 150,000 Limbs⁴are Lost Every Year because of PAD




50% Mortality Rate⁴ Associated with PAD after Limb Loss



3. Peripheral Vascular Devices Medtech 360 Market Analysis US 2017. (2016, December). Millenium Research Group, Inc.

4. https://www.cookmedical.com/peripheral-intervention/10-facts-a12tperipheral-arterial-disease/





2.35 mm

Aspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR)

2.0 mm

Aspiration capability and indicated for Peripheral Atherectomy and ISR **1.5 mm** Indicated for Perioheral



0.9 mm Indicated for Peripheral Atherectomy

Why wavelength matters

Each type of tissue interacts differently with a given wavelength The Auryon System produces a photon energy of 3.5 eV, which is low enough to be nonreactive to vessel endothelium, but high enough to vaporize calcium. ^{6,7}

Why pulse width and amplitude matter

Greater amplitude is achieved with shorter pulses, which can deposit energy before thermal diffusion occurs The Auryon System has a pulse width of 10 to 25 ns, ensuring enough power to target the lesion and spare the vessel. ⁵



angiodynamics

Auryon. Instructions for use. AngioDynamics; 2019. 6. Herzog A, Bogdan S, Glikson M, Ishaaya AA, Love C. Selective tissue ablation using laser radiation at 355 nm in lead extraction by a hybrid catheter; a preliminary report. Lasers Surg Med. 2016;48(3):281-287.
 Spectranetics Corporation. CVX-300 Excimer Laser System: Operator's Manual. Version 28. 2019:1-56.


INNOVATION DOCTORS NEED

Expands treatment options and help preserve patient's quality of life



PROBE PLACEMENT

NanoKnife can be confidently used in all segments of an organ.^{10.11}



DECELLULARIZATION

Destroys targeted tissue with precise treatment margins.^{10,11}



NON-THERMAL

Spares vital structures by retaining the structural integrity of tissue.^{12,13}



REVASCULARIZATION


Facilitates functional tissue regeneration post-ablation.^{12,13}


🚸 angiodynamics


Li Buidance for Selection of NanoKnife Probe Array Configuration and Ablation parameters for the Treatment of Stage III Pancreatic Cancer.
 Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV, Reijke TM, Siriwardana AR, Böhm M, de la Rosette JJ, Stricker PD. Impact on genitourinary function and quality of life following focal inversible electroporation of different prostate segments. Diagn Interv Radiol. 2018 Sep.24(5):268-275. doi: 10.5152/dir.2018.17374. PMID: 30211680; PMCID: PMC6135060.
 Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PLoS One. 2011 Apr 14;6(4):e18831. doi: 10.1371/journal.pone.0018831. PMID: 21533143; PMCID: PMC3077412.

THE NANOKNIFE SYSTEM

Estimated # of U.S. Patients Diagnosed in 2021'







PRESERVE Prostate IDE



SUO-CTC is a clinical research investigator network of 500+ members from more than 250 clinical sites in the US and Canada.

37	SUO-CTC US sites responded to Call for Sites
Up to 20	Sites to be selected, focused on geographic and demographic diversity, high-volume focal therapy institutions
100	Intermediate-risk patients enrolled through one year follow up

Primary endpoint: Rate of negative in-field biopsy at I year



angiodynamics

FINANCIALS



First Quarter Highlights

Financial Performance

\$ in thousands (except per share data)

	Q1 FY2022	Q1 FY2021	YOY Change
Revenue	\$76,971	\$70,216	9.6%
Gross Margin	52.1%	50.9%	120 bps
Net Loss	(\$6,972)	(\$4,268)	(\$2,704)
GAAP EPS	(\$0.18)	(\$0.11)	(\$0.07)
Adjusted EPS	(\$0.02)	\$0.02	(\$0.04)
Adjusted EBITDA	\$3,570	\$4,466	(\$896)

To view the Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS visit: investors.angiodynamics.com.

First Quarter FY2022 Results (unaudited)

\$ in thousands (except per share data)	Q1 FY2022	Q1 FY2021	Change
Revenue	\$76,971	\$70,216	9.6%
Med Tech	\$17,619	\$10,486	68.0%
Med Device	\$59,352	\$59,730	(0.6%)
Endovascular Therapies	\$38,058	\$29,857	27.5%
Vascular Access	\$24,957	\$28,105	(11.2)%*
Oncology	\$13,956	\$12,254	13.9%
United States	\$64,464	\$54,108	19.1%
International	\$12,507	\$16,108	(22.4%)
Net Loss	(\$6,972)	(\$4,268)	(\$2,704)
Non-GAAP Adjusted Net Income (Loss)	(\$887)	\$618	(\$1,505)
GAAP EPS	(\$0.18)	(\$0.11)	(\$0.07)
Non-GAAP Adjusted EPS	(\$0.02)	\$0.02	(\$0.04)
Gross Margin	52.1%	50.9%	120 bps
Adjusted EBITDA	\$3,570	\$4,466	(\$896)

\$ in thousands	Q1 FY2022	Q4 FY2021	Change
Cash	\$35,472	\$48,161	(\$12,689)
Debt	\$25,000	\$20,000	\$5,000
Net Cash	\$10,472	\$28,161	(\$17,689)

* Excluding the impact of the \$5.2 million NHS order in the prior year VA was up 9.0%.

angiodynamics

To view the Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS visit: investors.angiodynamics.com.

STRATEGIC TRANSFORMATION



PURSUE LARGER, FASTER GROWING MARKETS

Active portfolio management enables us to compete in larger, faster growing markets relying on technology & innovation to produce measurable patient outcomes

DEPLOY FOCUSED RESOURCE DEVELOPMENT

Resource deployment focused in areas that offer better opportunities for success

DRIVE PORTFOLIO TRANSFORMATION

Portfolio transformation & strength driven by R&D, M&A, and Clinical & Regulatory

ATTRACT AND RETAIN TOP TALENT

Strong and innovative portfolio combined with top talent drives value